Trials
1 active
4 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “* Dosage form: Tablet * Administration route: Oral, once a day”In the company’s words, NCT06954961 on ClinicalTrials.gov
- Tested for
- Breast Cancer
- Main trialPhase 3
- “This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.”In the company’s words, NCT06954961 on ClinicalTrials.gov
Other drugs for Breast Cancer
- ElacestrantStemline Therapeutics, Inc. · Phase 3
- YL202MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- SPH4336Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- NiraparibGSK · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
Coming up1
- 30 NovPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Nov 2026 | A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | |
| Phase 1Completed | 23 Dec 2021 | Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects | |
| Phase 1Completed | 2 Aug 2022 | Study in Healthy Adult Female Subjects | |
| Phase 1Completed | 18 Oct 2023 | A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026